Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Neurocrine Bioscienc
(NQ:
NBIX
)
152.81
+0.24 (+0.16%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Neurocrine Bioscienc
< Previous
1
2
3
4
5
6
7
8
Next >
Analyst Ratings for Neurocrine Biosciences
August 21, 2023
Via
Benzinga
Analyst Ratings for Neurocrine Biosciences
August 02, 2023
Via
Benzinga
Earnings Outlook For Neurocrine Biosciences
July 31, 2023
Via
Benzinga
Confidence Boost From Ingrezza Sales: Analyst Upgrades Neurocrine Biosciences
July 06, 2023
BMO Capital Markets has upgraded Neurocrine Biosciences Inc (NASDAQ: NBIX) from Underperform to Market Perform, with a price target of $96,
Via
Benzinga
What To Know About BMO Capital's Upgrade of Neurocrine Biosciences
July 06, 2023
Via
Benzinga
Expert Ratings for Neurocrine Biosciences
June 30, 2023
Via
Benzinga
What 15 Analyst Ratings Have To Say About Neurocrine Biosciences
June 05, 2023
Via
Benzinga
Neurocrine Biosciences's Return On Capital Employed Overview
May 08, 2023
Via
Benzinga
Neurocrine Biosciences Clocks 35% Revenue Growth In Q1, Misses On Bottom-Line Performance
May 03, 2023
Via
Benzinga
Neurocrine Biosciences: Q1 Earnings Insights
May 03, 2023
Via
Benzinga
Neurocrine Biosciences's Earnings: A Preview
May 02, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2023
July 06, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023
May 04, 2023
Via
Benzinga
What 15 Analyst Ratings Have To Say About Neurocrine Biosciences
April 17, 2023
Via
Benzinga
Expert Ratings for Neurocrine Biosciences
March 30, 2023
Via
Benzinga
Analyst Expectations for Neurocrine Biosciences's Future
March 03, 2023
Via
Benzinga
3 Pharma Stocks That Could See a Surge in Demand in 2023
April 24, 2023
These pharma stocks to buy are poised for long-term growth in the trillion-dollar biotechnology space, offering tremendous upside ahead
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023
March 30, 2023
Via
Benzinga
3 Growth Stocks That Could Disrupt the Healthcare Industry
March 13, 2023
These healthcare growth stocks will continue to provide steady and consistent returns, rewarding smart investors over time.
Via
InvestorPlace
Neurocrine Bio Tops Fourth-Quarter Views As Profit Skyrockets
February 06, 2023
Neurocrine also topped fourth-quarter revenue expectations on Monday.
Via
Investor's Business Daily
Neurocrine Biosciences Earnings Preview
February 03, 2023
Via
Benzinga
Why Voyager Therapeutics Stock Is Sinking This Week
January 20, 2023
Investors are taking profits on this red-hot stock this week.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2023
March 03, 2023
Via
Benzinga
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
February 14, 2023
From
Sentia Medical Sciences, Inc.
Via
GlobeNewswire
Five Best And Worst Performing Healthcare Stocks In January 2023
February 05, 2023
After a sub-par performance in 2021, healthcare stocks outperformed the S&P 500 in 2022. As well, 2023 is expected to be another promising year for the sector. Let’s take a look at the five best and...
Via
Talk Markets
Earnings Scheduled For February 6, 2023
February 06, 2023
Companies Reporting Before The Bell • Cummins (NYSE:CMI) is projected to report quarterly earnings at $4.56 per share on revenue of $7.21 billion.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
February 03, 2023
Via
Benzinga
Analyst Views Karuna Therapeutics' New Licensing Deal 'As Intriguing'
February 03, 2023
Via
Benzinga
Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
January 25, 2023
Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment.
Via
MarketBeat
7 A-Rated Stocks to Buy for Less Than $25
January 24, 2023
These seven stocks to buy for less than $25 per share are strong opportunities in today's resilient yet uncertain market.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.